This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
American Heart Association.Heart disease and stroke statistics – 2004 Update.Dallas, TX: American Heart Association; 2003.
2.
MillsR.M., YoungJ.B.Practical Approaches to the Treatment of Heart Failure.Baltimore, MD: Williams & Wilkins; 1998, 2–17.
3.
KonstamM., DracupK., BakerD.Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline No 11. AHCPR Publication No 94-0612. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; June 1994.
4.
JessupM., BrozenaS.Heart failure. N Engl J Med.2003; 348: 2007–18.
5.
Heart Failure Society of America.HFSA Guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction – pharmacological approaches. J Card Fail.1999; 5: 357–82.
6.
HuntS.A., BakerD.W., ChinM.H.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol.2001; 38: 2101–13.
7.
WeberK.T.Aldosterone in congestive heart failure. N Engl J Med.2001; 345: 1689–97.
8.
ChaA.J., MalechaS.E., JudgeK.W.Aldosterone, a new application of its role in heart failure. Pharmacotherapy.2000; 20: 1107–15.
SilvestreJ.S., HeymesC., OubenaissaA.Activation of cardiac aldosteroneproduction in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation.1999; 99: 2694–701.
11.
JessupM.Aldosterone blockade and heart failure. N Engl J Med.2003; 348: 1380–2.
12.
StaessenJ., LijnenP., FagardR.Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol.1981; 91: 457–65.
13.
PittB.“Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther.1995; 9: 145–9.
14.
SkluthH.A., GumsJ.G.Spironolactone: A re-examination. DICP.1990; 24: 52–9.
15.
PittB.Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation.2003; 108: 1790–4.
16.
PittB., ZannadF., RemmeW.J.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med.1999; 341: 709–17.
17.
PittB., RemmeW., ZannadF.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med.2003; 348: 1309–21.
18.
GlickH.A., OrzolS.M., TooleyJ.F.Economic evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of patients with severe heart failure. Cardiovasc Drugs Ther.2002; 16: 53–9.
19.
SpertusJ.A., TooleyJ., JonesP.Expanding the outcomes in clinical trials of heart failure: The quality of life and economic components of EPHESUS (Eplerenone's Neurohormonal Efficacy and Survival Study). Am Heart J.2002; 143: 636–42.
20.
JarmanP.R., MatherH.M.Diabetes may be independent risk factor for hyperkalemia. [letter]. BMJ.2003; 327: 812.
21.
BozkurtB., AgostonI., KnowltonA.A.Complications of inappropriate use of spironolactone in heart failure: When an old medicine spirals out of new guidelines. J Am Coll Cardiol.2003; 41: 211–4.
22.
SchepkensH., VanholderR., BilliouwJ-M, LameireN.Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med.2001; 110: 438–41.
